Brolucizumab (DLX1008) is a high-affinity single-chain anti-VEGF-A antibody fragment, demonstrating a dissociation constant (K_D) of 1.05 pM. This monoclonal antibody is engineered for precise targeting and inhibition of vascular endothelial growth factor A (VEGF-A), a key molecule involved in angiogenesis. Brolucizumab is utilized primarily in oncological research to study and inhibit tumor-induced blood vessel formation, offering potential insights into cancer therapy mechanisms.
Brolucizumab (DLX1008) is a high-affinity single-chain anti-VEGF-A antibody fragment, demonstrating a dissociation constant (K_D) of 1.05 pM. This monoclonal antibody is engineered for precise targeting and inhibition of vascular endothelial growth factor A (VEGF-A), a key molecule involved in angiogenesis. Brolucizumab is utilized primarily in oncological research to study and inhibit tumor-induced blood vessel formation, offering potential insights into cancer therapy mechanisms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
